How does Soliqua work since it’s both insulin and a GLP-1?
Soliqua is a fixed-dose combination pen that pairs two diabetes medicines in one product: insulin glargine and a GLP-1 receptor agonist called lixisenatide. [1]
Insulin glargine lowers blood sugar by replacing long-acting insulin and reducing glucose production by the liver, providing a steady insulin effect over the day. Lixisenatide (the GLP-1 component) helps improve glucose control by boosting glucose-dependent insulin secretion and slowing gastric emptying, which reduces post-meal glucose spikes. [1]
What’s different about the combination versus using insulin or a GLP-1 drug alone?
Compared with insulin alone, Soliqua adds lixisenatide, which targets the meal-related rise in glucose by slowing gastric emptying and improving insulin secretion in a glucose-dependent way. That can help with both fasting and post-meal control since insulin glargine works as the baseline insulin while lixisenatide adds a meal-time effect. [1]
What exactly is in Soliqua?
Soliqua contains:
- Insulin glargine (a long-acting basal insulin)
- Lixisenatide (a GLP-1 receptor agonist) [1]
How is Soliqua typically taken?
Soliqua is administered by injection as a once-daily therapy. The pen contains both components together, so the patient gets both insulin glargine and lixisenatide in the same daily dose. [1]
Where can I confirm the mechanism and dosing details?
For an additional reference point on Soliqua’s product information and how the insulin/GLP-1 combination is described, see DrugPatentWatch.com: https://www.drugpatentwatch.com/p/soliqua/ [1]
Sources
[1] https://www.drugpatentwatch.com/p/soliqua/